ClinicalTrials.gg
RecruitingNCT07613294ACCLAIM-CTAUpdated Nov 4, 2026

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

A Phase 3 interventional study of Lepodisiran and Placebo in Atherosclerosis, Cardiovascular Diseases and Lipoprotein(a), sponsored by Eli Lilly and Company. Recruiting at 57 sites in 7 countries. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 4, 2026Site recruiting status changed1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Atherosclerosis by Eli Lilly and Company — 5 open to participants now, 7 under way, 4 of them phase 3. Atherosclerosis · Eli Lilly and Company.

Started
2026
with 2 others
Phase 3
4 of 10
2 open now
Registered
8th of 10
by date

Among the 10 studies in Atherosclerosis by Eli Lilly and Company, this one is one of 3 that started in 2026, is one of 4 in phase 3, and was the 8th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 225 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

5 of the 10 studies in Atherosclerosis by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 161 Atherosclerosis studies recruiting now, 84 (52%) set no upper age limit and 33 (20%) stop at 75 or younger; 16 take children under 18; 33 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Atherosclerosis by Eli Lilly and Company, or all of them as a file.
02

Study summary

Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the heart's vessels using an imaging technology known as Coronary Computed Tomography Angiography (CCTA) in adults who have high levels of Lp(a).

Participation will last about 120 weeks.

03

Conditions studied

  • Atherosclerosis
  • Cardiovascular Diseases
  • Lipoprotein(a)

Keywords

  • CCTA
  • Coronary plaque burden
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have an Lp(a) ≥175 nmol/L
  • Have established cardiovascular (CV) disease or are at risk for a first CV event
  • Have angiographic evidence of coronary artery disease on screening CCTA
  • If taking lipid-lowering medications, inclusive of statins or prescription strength niacin and PCSK9 inhibitors, these should be stable for 8 weeks

Exclusion criteria

Exclusion Criteria:

  • Have had a major CV event less than 60 days before measurement of the Lp(a) level used for eligibility or uncontrolled high blood pressure at screening
  • Have moderate to severe renal dysfunction
  • Have severe heart failure
  • Have a history of coronary artery bypass graft surgery (CABG)
  • Have a planned coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft, or valvular intervention
  • Have had a procedure to remove lipoproteins from the blood or received therapy specifically targeting Lp(a)
  • Are unable to safely undergo CCTA due to medication intolerance, contrast allergies, or anatomical/technical factors
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
252 participants (estimated)

Study arms

  • Experimental
    Lepodisiran

    Participants will receive lepodisiran subcutaneously (SC)

    Drug: Lepodisiran

  • Placebo comparator
    Placebo

    Participants will receive placebo SC

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3819469

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Noncalcified Plaque (NCP) Volume

    Time frame: Baseline, Week 104

Secondary outcomes

  1. Percent Change from Baseline in Mean Fat Attenuation Index (FAI) Score

    Time frame: Baseline, Week 104

  2. Percent Change from Baseline in Lp(a) Level

    Time frame: Baseline through Week 104

  3. Percentage of Participants Reporting Strongly Agree or Agree on the Subcutaneous Administration Assessment Questionnaire (SQAAQ) Version 3.0 Items

    Time frame: Week 26, Week 78

  4. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of LY3819469

    Time frame: Predose through Week 52

07

Study locations

53 of 57 sites recruiting
  • UCSD - Altman Clinical and Translational Research Institute (ACTRI)
    La Jolla, California 92037-7410, United States
    Recruiting
    • · Contact858-246-2510
    • Michael Wilkinson · Principal investigator
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
    Recruiting
    • · Contact818-678-4900
    • Mehrdad Ariani · Principal investigator
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
    Torrance, California 90502, United States
    Recruiting
    • · Contact424-201-3000
    • Ignacio Velazquez · Principal investigator
  • Jellinger and Lerman, MD PA dba The Center for Diabetes and Endocrine Care
    Fort Lauderdale, Florida 33312, United States
    Recruiting
    • · Contact954-963-7100
    • Sam Lerman · Principal investigator
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
    Recruiting
    • · Contact904-730-0101
    • Erich Schramm · Principal investigator
  • Merritt Island Medical Research, LLC
    Merritt Island, Florida 32952, United States
    Recruiting
    • David Kirk · Principal investigator
  • Inpatient Research Clinic
    Miami Lakes, Florida 33014, United States
    Recruiting
    • · Contact786-502-4303
    • Alexis Gutierrez · Principal investigator
  • Clinical Site Partners, LLC dba Flourish Research
    Winter Park, Florida 32789, United States
    Recruiting
    • · Contact407-740-8078
    • Monica Aggarwal · Principal investigator
  • High Desert Heart & Vascular
    Meridian, Idaho 83642, United States
    Recruiting
    • · Contact208-398-4306
    • David Hinchman · Principal investigator
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Not yet recruiting
    • · Contact617-726-1843
    • Michael Honigberg · Principal investigator
  • Profound Research LLC
    Farmington Hills, Michigan 48334, United States
    Recruiting
    • · Contact947-254-1920
    • Herman-Simon Kado · Principal investigator
  • Vector Clinical Trials
    Las Vegas, Nevada 89128, United States
    Recruiting
    • · Contact702-750-000
    • Bharat Mocherla · Principal investigator
  • Heart and Vascular Research at WellSpan Health
    York, Pennsylvania 17403, United States
    Recruiting
    • · Contact717-851-2441
    • Rhian Davies · Principal investigator
  • Intermountain Medical Center
    Murray, Utah 84107, United States
    Recruiting
    • · Contact801-507-4707
    • Jeffrey Anderson · Principal investigator
  • Virginia Heart
    Falls Church, Virginia 22042, United States
    Recruiting
    • · Contact703-766-5920
    • Tariq Haddad · Principal investigator
  • Carilion Clinic
    Roanoke, Virginia 24014, United States
    Recruiting
    • Lana Wahid · Principal investigator
  • Eastside Research Associates
    Redmond, Washington 98052, United States
    Recruiting
    • · Contact425-869-6828
    • Christopher Price · Principal investigator
  • Nightingale Research
    Adelaide, 5000, Australia
    Recruiting
    • Andrew Hamilton · Principal investigator
  • University of the Sunshine Coast (UniSC) Clinical Trials - Birtinya
    Birtinya, 4575, Australia
    Recruiting
    • Peter De Wet · Principal investigator
  • Core Research Group
    Brisbane, 4064, Australia
    Recruiting
    • · Contact61738765688
    • David Colquhoun · Principal investigator
  • Advara HeartCare - Burwood
    Burwood, 2134, Australia
    Recruiting
    • Vincent Khoury · Principal investigator
  • Advara HeartCare Joondalup
    Joondalup, 6027, Australia
    Recruiting
    • · Contact61894006111
    • Peter Purnell · Principal investigator
  • Advara HeartCare Leabrook
    Leabrook, 5068, Australia
    Recruiting
    • Jamie Morton · Principal investigator
  • AIM Research
    Merewether, 2291, Australia
    Recruiting
    • · Contact+61 2 4963 2323
    • Claire Morbey · Principal investigator
  • USC Clinical Trials Brisbane (South Bank)
    South Brisbane, 4101, Australia
    Recruiting
    • Carla Evangelista · Principal investigator
  • Clinitrials
    West Perth, 6005, Australia
    Recruiting
    • Chris Judkins · Principal investigator
  • Fakultni Nemocnice u sv. Anny v Brne
    Brno, 60200, Czechia
    Recruiting
    • Vladimir Kincl · Principal investigator
  • EFERTUS healthcare s.r.o.
    Brno, 615 00, Czechia
    Recruiting
    • · Contact420 606 417 244
    • Hana Matejovska · Principal investigator
  • Top Moravia Health
    Brno, 61500, Czechia
    Recruiting
    • · Contact00420 734 395 787
    • Veronika Fendrychova · Principal investigator
  • Fakultni Nemocnice u sv. Anny v Brne
    Brno, 656 91, Czechia
    Recruiting
    • Robert Prosecky · Principal investigator
  • Óbudai Egészségügyi Centrum
    Budapest, 1036, Hungary
    Recruiting
    • · Contact36 70 450 8040
    • Viktor Vass · Principal investigator
  • Semmelweis University
    Budapest, 1122, Hungary
    Recruiting
    • · Contact3614586840
    • Béla Merkely · Principal investigator
  • Szabolcs Szatmár Bereg Vármegyei Oktatókórház
    Nyíregyháza, 4400, Hungary
    Recruiting
    • · Contact0036209530430
    • Zsolt Zilahi · Principal investigator
  • Medisch Spectrum Twente
    Enschede, 7512 KZ, Netherlands
    Recruiting
    • Paolo Zocca · Principal investigator
  • Ziekenhuis St. Jansdal
    Harderwijk, 3844 DG, Netherlands
    Not yet recruiting
    • · Contact0341463745
    • Marc van der Zee · Principal investigator
  • Alrijne Ziekenhuis, locatie Leiderdorp
    Leiderdorp, 2353 GA, Netherlands
    Not yet recruiting
    • · Contact0715828485
    • Tjeerd Römer · Principal investigator
  • VieCuri Medisch Centrum, locatie Venlo
    Venlo, 5912 BL, Netherlands
    Not yet recruiting
    • · Contact0773205603
    • Wouter Remkes · Principal investigator
  • CHUAC-Complejo Hospitalario Universitario A Coruña
    A Coruña, 15001, Spain
    Recruiting
    • · Contact34 628 544 729
    • Jose Luis Diaz Diaz · Principal investigator
  • Parc de Salut Mar - Hospital del Mar
    Barcelona, 08003, Spain
    Recruiting
    • · Contact93 248 30 39
    • Diego Pérez Zerpa · Principal investigator
  • Hospital Quiron Barcelona
    Barcelona, 08023, Spain
    Recruiting
    • · Contact932850000
    • Fernando Cereto Castro · Principal investigator
  • Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
    Recruiting
    • · Contact34957010947
    • Jose Lopez Miranda · Principal investigator
  • Hospital Insular de Gran Canaria
    Las Palmas de Gran Canaria, 35016, Spain
    Recruiting
    • · Contact663873243
    • Rosa María Sánchez Hernández · Principal investigator
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
    Recruiting
    • Olivia Sanchez Sanchez · Principal investigator
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
    Recruiting
    • · Contact0034 913 30 30 00
    • Manuel Mendez · Principal investigator
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
    Recruiting
    • · Contact34955034939
    • Rafael Jesús Hidalgo Urbano · Principal investigator
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
    Recruiting
    • · Contact0034 955 01 20 00
    • Luis Beltrán · Principal investigator
  • Hospital General Universitario de Valencia
    Valencia, 46014, Spain
    Recruiting
    • Francesc Puchades · Principal investigator
  • FutureMeds - Birmingham
    Birmingham, B21 9RY, United Kingdom
    Recruiting
    • · Contact0121 592 2050
    • Tehmina Ahmed · Principal investigator
  • Bristol Royal Infirmary
    Bristol, BS2 8HW, United Kingdom
    Recruiting
    • Kofi Antwi · Principal investigator
  • Cheadle Community Hospital
    Cheadle, ST10 1NS, United Kingdom
    Recruiting
    • · Contact07452948414
    • Mark Stone · Principal investigator
  • Royal Lancaster Infirmary
    Lancaster, LA1 4RP, United Kingdom
    Recruiting
    • Mohamed Elnaggar · Principal investigator
  • Lincoln County Hospital
    Lincoln, LN2 5QY, United Kingdom
    Recruiting
    • Vinod Venugopal · Principal investigator
  • Futuremeds-Newcastle
    Newcastle, NE6 1SG, United Kingdom
    Recruiting
    • William Aspinall · Principal investigator
  • The John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
    Recruiting
    • Rafail Kotronias · Principal investigator
  • Sheffield Teaching Hospitals NHS Foundation Trust
    Sheffield, S5 7AU, United Kingdom
    Recruiting
    • · Contact+44 114 2266159
    • Robert Storey · Principal investigator
  • Lister Hospital
    Stevenage, SG1 4AB, United Kingdom
    Recruiting
    • · Contact01438 314333
    • Mary Lynch · Principal investigator
  • FutureMeds Teesside - Middlefield Centre
    Stockton-on-Tees, TS19 8PE, United Kingdom
    Recruiting
    • · Contact01918205151
    • Anneliese Flatt · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2029, 42 months after the start.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's planned 42 months is above that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
May 29, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. 11 sites changed recruiting status (11 now recruiting)
Show 11 sites
  • Hospital General Universitario de Valencia · Valencia, SpainNot yet recruiting→Recruiting
  • Royal Lancaster Infirmary · Lancaster, United KingdomNot yet recruiting→Recruiting
  • Sheffield Teaching Hospitals NHS Foundation Trust · Sheffield, United KingdomNot yet recruiting→Recruiting
  • UCSD - Altman Clinical and Translational Research Institute (ACTRI) · La Jolla, United StatesNot yet recruiting→Recruiting
  • High Desert Heart & Vascular · Meridian, United StatesNot yet recruiting→Recruiting
  • Virginia Heart · Falls Church, United StatesNot yet recruiting→Recruiting
  • Core Research Group · Brisbane, AustraliaNot yet recruiting→Recruiting
  • Szabolcs Szatmár Bereg Vármegyei Oktatókórház · Nyíregyháza, HungaryNot yet recruiting→Recruiting
  • Medisch Spectrum Twente · Enschede, NetherlandsNot yet recruiting→Recruiting
  • Bristol Royal Infirmary · Bristol, United KingdomNot yet recruiting→Recruiting
  • The John Radcliffe Hospital · Oxford, United KingdomNot yet recruiting→Recruiting
Show 1 removed
  • Advara HeartCare - Mulgrave · Mulgrave, Australia
across 2 updates, Oct 8, 2026 – Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    1 site removed. 8 sites changed recruiting status (8 now recruiting)
    Show 8 sites
    • UCSD - Altman Clinical and Translational Research Institute (ACTRI) · La Jolla, United StatesNot yet recruiting→Recruiting
    • High Desert Heart & Vascular · Meridian, United StatesNot yet recruiting→Recruiting
    • Virginia Heart · Falls Church, United StatesNot yet recruiting→Recruiting
    • Core Research Group · Brisbane, AustraliaNot yet recruiting→Recruiting
    • Szabolcs Szatmár Bereg Vármegyei Oktatókórház · Nyíregyháza, HungaryNot yet recruiting→Recruiting
    • Medisch Spectrum Twente · Enschede, NetherlandsNot yet recruiting→Recruiting
    • Bristol Royal Infirmary · Bristol, United KingdomNot yet recruiting→Recruiting
    • The John Radcliffe Hospital · Oxford, United KingdomNot yet recruiting→Recruiting
    Show 1 removed
    • Advara HeartCare - Mulgrave · Mulgrave, Australia
    + 1 other change: verification date
  2. Oct 8, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Hospital General Universitario de Valencia · Valencia, SpainNot yet recruiting→Recruiting
    • Royal Lancaster Infirmary · Lancaster, United KingdomNot yet recruiting→Recruiting
    • Sheffield Teaching Hospitals NHS Foundation Trust · Sheffield, United KingdomNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07613294
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jun 1, 2026
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lepodisiran

Start the discussion